We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.
- Authors
Portelinha, Ana; da Silva Ferreira, Mariana; Erazo, Tatiana; Jiang, Man; Asgari, Zahra; de Stanchina, Elisa; Younes, Anas; Wendel, Hans-Guido
- Abstract
Spontaneous whole genome duplication and the adaptive mutations that disrupt genome integrity checkpoints are infrequent events in B cell lymphomas. This suggests that lymphomas might be vulnerable to therapeutics that acutely trigger genomic instability and polyploidy. Here, we report a therapeutic combination of inhibitors of the Polo-like kinase 4 and BCL-2 that trigger genomic instability and cell death in aggressive lymphomas. The synthetic lethality is selective for tumor cells and spares vital organs. Mechanistically, inhibitors of Polo-like kinase 4 impair centrosome duplication and cause genomic instability. The elimination of polyploid cells largely depends on the pro-apoptotic BAX protein. Consequently, the combination of drugs that induce polyploidy with the BCL-2 inhibitor Venetoclax is highly synergistic and safe against xenograft and PDX models. We show that B cell lymphomas are ill-equipped for acute, therapy-induced polyploidy and that BCL-2 inhibition further enhances the removal of polyploid lymphoma cells. Genomic instability occurs infrequently in in diffuse large B cell lymphoma (DLBCL), suggesting a therapeutic vulnerability. Here, the authors identify a synergistic combination between the induction of polyploidy by a PLK4 inhibitor and a BCL-2 inhibitor in DLBCL.
- Subjects
POLO, Marco, 1254-ca. 1323; POLYPLOIDY; B cell lymphoma; DRUG side effects; BAX protein; LYMPHOMAS; ANAPLASTIC lymphoma kinase
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-37216-2